Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 174Neoplasm Metastasis 139Neoplasms 133Leukemia, Myeloid, Acute 127Colorectal Neoplasms 126Breast Neoplasms 113Melanoma 88Ovarian Neoplasms 87Prostatic Neoplasms 86Recurrence 84Multiple Myeloma 79Pancreatic Neoplasms 74Squamous Cell Carcinoma of Head and Neck 72Glioblastoma 71Lung Neoplasms 70Lymphoma, Non-Hodgkin 62Myelodysplastic Syndromes 60Triple Negative Breast Neoplasms 56Stomach Neoplasms 52Glioma 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Endometrial Neoplasms 47Carcinoma, Renal Cell 47Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 44Brain Neoplasms 43Carcinoma, Hepatocellular 41Sarcoma 39Advanced Solid Tumors 39Lymphoma, Follicular 38

Interventions

darolutamide 1Rifampin 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Refractory or Relapsed Solid Tumors × 90 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡